Many genes and signalling pathways controlling cell proliferation, death and differentiation,
as well as genomic integrity, are involved in cancer development. New techniques, such as …

While several prognostic factors have been identified in breast carcinoma, the clinical outcome
remains hard to predict for individual patients. Better predictive markers are needed to …

Background Trastuzumab improves survival in the adjuvant treatment of HER-positive
breast cancer, although combined therapy with anthracycline-based regimens has been …

Expression of the transmembrane glycoprotein EpCam (epithelial cellular adhesion
molecule) occurs in normal epithelium of different organs and was described in carcinomas of …

The prognosis of prostate cancer is mainly determined by thepresence or absence of metastases.
Nevertheless, the metastasic pathways in prostate cancer are not entirely understood. …

Members of the recently recognized SRC-1 family of transcriptional coactivators interact with
steroid hormone receptors to enhance ligand-dependent transcription. AIB1, a member of …

Background Many cases of hereditary breast cancer are due to mutations in either the
BRCA1 or the BRCA2 gene. The histopathological changes in these cancers are often …

The goal of this review is to systematically address a number of issues raised in the American
Society of Clinical Oncology–College of American Pathologists (ASCO-CAP) guidelines …

Prostate cancer development and progression is driven by the accumulation of genetic
changes, the nature of which remains incompletely understood. To facilitate high-throughput …

Tissue microarray (TMA) technology allows rapid visualization of molecular targets in
thousands of tissue specimens at a time, either at the DNA, RNA or protein level. The technique …